SOHM

SOHM Inc. is a vertically integrated biopharmaceutical company with a foundation in generic drugs and nutraceuticals, now expanding into advanced biotechnology. Founded in 2003 and headquartered in Chino, California, the company leverages global manufacturing partnerships and a proprietary gene editing platform named ABBIE to pursue a dual strategy of commercial product sales and R&D for novel therapies. Its business model spans from revenue-generating generic and over-the-counter products to early-stage research in gene editing, aiming to create a pipeline that addresses both everyday wellness and incurable diseases.

Patented gene editing technology named ABBIE, aimed at developing novel treatments for incurable diseases and enhancing existing products. Platform details (e.g., CRISPR-based) are not publicly specified.

In generics and nutraceuticals, SOHM competes with numerous large, low-cost manufacturers and branded OTC companies. In gene editing, it would face competition from well-funded, specialized biotechs (e.g., CRISPR Therapeutics, Editas Medicine) and large pharmaceutical companies with internal platforms, all pursuing similar groundbreaking therapies.